Stock Track | ANI Pharmaceuticals Soars 5.35% in Pre-market on Strong Earnings Beat, Raised Guidance and $100M Buyback

Stock Track

May 08

ANI Pharmaceuticals' stock surged 5.35% during the pre-market session following the release of its first-quarter 2026 financial results, which significantly exceeded analyst expectations.

The company reported adjusted earnings per share of $2.05, beating the consensus estimate of $1.30 by 56.49%. Quarterly sales reached $237.462 million, surpassing the estimate of $207.565 million by 14.40%. This represents a year-over-year increase of over 20% for both metrics.

Adding to the positive sentiment, ANI Pharmaceuticals raised its full-year 2026 financial outlook. The company now forecasts adjusted EPS between $9.19 and $9.69, compared to the previous Ibes estimate of $9.07, and expects revenue in the range of $1,080 to $1,140 million, above the estimated $1,050 million. Furthermore, the Board of Directors authorized a new $100 million share repurchase program.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1124540519"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1124540519\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1124540519?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 18:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124540519","market":"sg","top_or_hot":-1,"title":"Stock Track | ANI Pharmaceuticals Soars 5.35% in Pre-market on Strong Earnings Beat, Raised Guidance and $100M Buyback","media":"Stock Track","content":"<p>ANI Pharmaceuticals' stock surged 5.35% during the pre-market session following the release of its first-quarter 2026 financial results, which significantly exceeded analyst expectations.</p><p>The company reported adjusted earnings per share of $2.05, beating the consensus estimate of $1.30 by 56.49%. Quarterly sales reached $237.462 million, surpassing the estimate of $207.565 million by 14.40%. This represents a year-over-year increase of over 20% for both metrics.</p><p>Adding to the positive sentiment, ANI Pharmaceuticals raised its full-year 2026 financial outlook. The company now forecasts adjusted EPS between $9.19 and $9.69, compared to the previous Ibes estimate of $9.07, and expects revenue in the range of $1,080 to $1,140 million, above the estimated $1,050 million. Furthermore, the Board of Directors authorized a new $100 million share repurchase program.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ANI Pharmaceuticals Soars 5.35% in Pre-market on Strong Earnings Beat, Raised Guidance and $100M Buyback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ANI Pharmaceuticals Soars 5.35% in Pre-market on Strong Earnings Beat, Raised Guidance and $100M Buyback\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-08 18:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ANI Pharmaceuticals' stock surged 5.35% during the pre-market session following the release of its first-quarter 2026 financial results, which significantly exceeded analyst expectations.</p><p>The company reported adjusted earnings per share of $2.05, beating the consensus estimate of $1.30 by 56.49%. Quarterly sales reached $237.462 million, surpassing the estimate of $207.565 million by 14.40%. This represents a year-over-year increase of over 20% for both metrics.</p><p>Adding to the positive sentiment, ANI Pharmaceuticals raised its full-year 2026 financial outlook. The company now forecasts adjusted EPS between $9.19 and $9.69, compared to the previous Ibes estimate of $9.07, and expects revenue in the range of $1,080 to $1,140 million, above the estimated $1,050 million. Furthermore, the Board of Directors authorized a new $100 million share repurchase program.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANIP","symbol_name":"ANI Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1124540519","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124540519","pubTimestamp":1778237564,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ANI Pharmaceuticals' stock surged 5.35% during the pre-market session following the release of its first-quarter 2026 financial results, which significantly exceeded analyst expectations.The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ANIP":"ANI Pharmaceuticals, Inc."},"translate_title":"个股追踪|ANI Pharmaceuticals盘前飙升5.35%，因盈利强劲、指引上调和1亿美元回购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANIP":1},"content_text":"ANI Pharmaceuticals' stock surged 5.35% during the pre-market session following the release of its first-quarter 2026 financial results, which significantly exceeded analyst expectations.The company reported adjusted earnings per share of $2.05, beating the consensus estimate of $1.30 by 56.49%. Quarterly sales reached $237.462 million, surpassing the estimate of $207.565 million by 14.40%. This represents a year-over-year increase of over 20% for both metrics.Adding to the positive sentiment, ANI Pharmaceuticals raised its full-year 2026 financial outlook. The company now forecasts adjusted EPS between $9.19 and $9.69, compared to the previous Ibes estimate of $9.07, and expects revenue in the range of $1,080 to $1,140 million, above the estimated $1,050 million. Furthermore, the Board of Directors authorized a new $100 million share repurchase program.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}